N-Deacetylthiocolchicine

Cat. No.: HY-W072781: Data Sheet Handling Instructions
FAQs
Technical Support

N-Deacetylthiocolchicine is a tubulin inhibitor with an IC₅₀ value of 2.2 nM in MDR-negative MDA-MB 231 breast cancer cells. N-Deacetylthiocolchicine exerts antiproliferative activity by binding to tubulin to interfere with microtubule assembly, arresting cells in mitosis during the cell cycle. N-Deacetylthiocolchicine is promising for research of malignancies such as breast cancer.

For research use only. We do not sell to patients.

N-Deacetylthiocolchicine Chemical Structure

CAS No. : 2731-16-0

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	ED₅₀	0.0077 μg/mL Compound: 4	Cytotoxicity against human A549 cells after 2 days Cytotoxicity against human A549 cells after 2 days	[PMID: 20542428]
A549	IC₅₀	11 nM Compound: DTCOLCH	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 34592435]
A549	IC₅₀	24.1 nM Compound: 3	Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
BALB/3T3	IC₅₀	15.4 nM Compound: DTCOLCH	Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34592435]
BALB/3T3	IC₅₀	223 nM Compound: 3	Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
CA46	IC₅₀	38 μM Compound: 6a	Inhibits the growth of the human Burkitt lymphoma CA46 cell Inhibits the growth of the human Burkitt lymphoma CA46 cell	[PMID: 9083485]
DLD-1	IC₅₀	1180 nM Compound: 7	Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
DU-145	ED₅₀	0.0018 μg/mL Compound: 4	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 20542428]
H9	EC₅₀	0.013 μM Compound: 10	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 1919593]
H9	IC₅₀	0.013 μM Compound: 10	Antiviral activity against HIV1 HTLV-3B in human H9 cells after 3 days by p24 antigen capture assay Antiviral activity against HIV1 HTLV-3B in human H9 cells after 3 days by p24 antigen capture assay	[PMID: 1919593]
HCT-8	ED₅₀	0.005 μg/mL Compound: 4	Cytotoxicity against human HCT8 cells after 2 days Cytotoxicity against human HCT8 cells after 2 days	[PMID: 20542428]
HeLa	GI₅₀	0.014 μM Compound: 11a	Antiproliferative activity against human HeLa cells assessed as reduction in cell number incubated for 72 hrs Antiproliferative activity against human HeLa cells assessed as reduction in cell number incubated for 72 hrs	[PMID: 30996805]
HepG2	GI₅₀	0.018 μM Compound: 11a	Antiproliferative activity against human HepG2 cells assessed as reduction in cell number incubated for 72 hrs Antiproliferative activity against human HepG2 cells assessed as reduction in cell number incubated for 72 hrs	[PMID: 30996805]
IGROV-1	IC₅₀	0.023 μM Compound: 2	Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis	[PMID: 19833515]
KB	ED₅₀	0.0018 μg/mL Compound: 4	Cytotoxicity against human KB cells after 2 days Cytotoxicity against human KB cells after 2 days	[PMID: 20542428]
L1210	IC₅₀	40 nM Compound: 31	In vitro cytotoxicity against L1210 (murine leukemia) cells. In vitro cytotoxicity against L1210 (murine leukemia) cells.	[PMID: 2299625]
LoVo	IC₅₀	10.3 nM Compound: DTCOLCH	Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 34592435]
LoVo	IC₅₀	1020 nM Compound: 7	Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
LoVo	IC₅₀	16.9 nM Compound: 3	Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
MCF7	GI₅₀	0.018 μM Compound: 11a	Antiproliferative activity against human MCF7 cells assessed as reduction in cell number incubated for 72 hrs Antiproliferative activity against human MCF7 cells assessed as reduction in cell number incubated for 72 hrs	[PMID: 30996805]
MCF7	IC₅₀	14.2 nM Compound: 3	Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
MCF7	IC₅₀	4200 nM Compound: 3	Anti tumor activity on human breast cancer cell line MDR-positive MCF-7 ADRr after 72 hours of treatment Anti tumor activity on human breast cancer cell line MDR-positive MCF-7 ADRr after 72 hours of treatment	[PMID: 10602712]
MCF7	IC₅₀	670 nM Compound: 7	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
MCF7	IC₅₀	9.5 nM Compound: DTCOLCH	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 34592435]
MDA-MB-231	IC₅₀	1260 nM Compound: 7	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
MDA-MB-231	IC₅₀	2.2 nM Compound: 3	Anti tumor activity on human breast cancer cell line MDR-negative MDA-MB 231 after 72 hours of treatment Anti tumor activity on human breast cancer cell line MDR-negative MDA-MB 231 after 72 hours of treatment	[PMID: 10602712]
SK-BR-3	ED₅₀	0.0016 μg/mL Compound: 4	Cytotoxicity against human SKBR3 cells after 2 days Cytotoxicity against human SKBR3 cells after 2 days	[PMID: 20542428]
SK-OV-3	IC₅₀	1.3 nM Compound: 7	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
SK-OV-3	IC₅₀	9.6 nM Compound: 7	Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]

Molecular Weight

373.47

Formula

C₂₀H₂₃NO₄S

CAS No.

2731-16-0

SMILES

COC1=C(C(C([C@@H](N)CC2)=C3)=CC=C(SC)C3=O)C2=CC(OC)=C1OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Gelmi ML, et al. N-deacetyl-N-aminoacylthiocolchicine derivatives: synthesis and biological evaluation on MDR-positive and MDR-negative human cancer cell lines. J Med Chem. 1999 Dec 16;42(25):5272-6. [Content Brief]

[2]. Barešić M, et al. Different Therapeutic Paths (Colchicine vs. Anakinra) in Two Patients With Schnitzler's Syndrome. Arch Rheumatol. 2016 Jul 11;31(4):377-380. [Content Brief]